The global spectrum of protein-coding pharmacogenomic diversity

Area of Science:

• Genomics and Personalized Medicine
• Pharmacogenomics
• Population Genetics

Background:

• Individual responses to medications are substantially influenced by genetic factors.
• Understanding pharmacogenomic variation is crucial for optimizing drug therapy and minimizing adverse events.
• Publicly available genomic datasets offer a valuable resource for extensive variation analysis.

Purpose of the Study:

• To comprehensively investigate pharmacogenomic variation using large-scale population data.
• To identify clinically relevant genetic variants and assess their distribution across global populations.
• To highlight the prevalence of rare variants and their potential impact on drug response.

Main Methods:

• Extraction of pharmacogenomic variation data from the 1000 Genomes Project Phase 3 dataset (2504 individuals, 26 populations).
• Identification and classification of genetic variants within 120 pharmacogenes.
• Analysis of variant frequencies, including rare variants (minor allele frequency <0.5%) and singletons, and calculation of fixation index (FST) for population differentiation.

Main Results:

• A total of 12,084 genetic variants were identified in 120 pharmacogenes, with 90% classified as rare.
• Common variation aligned with continental super-populations, and 23 pharmacogenes showed highly differentiated variants between populations.
• Over half (55.4%) of individuals carried loss-of-function variants, with significant super-population differences observed (e.g., East Asians 60.9% vs. Europeans 49.3%).

Conclusions:

• Genome sequencing effectively identifies clinically significant pharmacogenomic variations.
• Rare genetic variants are prevalent and play a critical role in the spectrum of drug response.
• Future research must incorporate rare variation analysis to fully understand genetic diversity's impact on pharmacogenomics.